Verus Capital Partners LLC cut its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 37.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 970 shares of the company’s stock after selling 573 shares during the period. Verus Capital Partners LLC’s holdings in Eli Lilly And Co were worth $135,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Stonebridge Financial Planning Group LLC increased its position in Eli Lilly And Co by 70.0% in the first quarter. Stonebridge Financial Planning Group LLC now owns 170 shares of the company’s stock worth $25,000 after purchasing an additional 70 shares during the last quarter. Pacitti Group Inc. acquired a new position in shares of Eli Lilly And Co during the fourth quarter worth about $25,000. Truvestments Capital LLC acquired a new position in Eli Lilly And Co in the first quarter valued at $27,000. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Eli Lilly And Co in the first quarter valued at $34,000. Finally, Bainco International Investors acquired a new stake in Eli Lilly And Co in the 1st quarter valued at about $34,000. 77.44% of the stock is owned by institutional investors.

Shares of Eli Lilly And Co stock traded down $1.66 during trading on Friday, hitting $161.20. 526,434 shares of the stock traded hands, compared to its average volume of 4,824,256. Eli Lilly And Co has a 52 week low of $101.36 and a 52 week high of $167.43. The stock has a market cap of $155.77 billion, a price-to-earnings ratio of 26.91, a PEG ratio of 1.46 and a beta of 0.24. The firm’s fifty day moving average is $153.45 and its 200-day moving average is $142.31. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 4.37.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Thursday, April 23rd. The company reported $1.75 earnings per share for the quarter, beating the consensus estimate of $1.48 by $0.27. Eli Lilly And Co had a return on equity of 194.18% and a net margin of 23.97%. The firm had revenue of $5.86 billion during the quarter, compared to the consensus estimate of $5.48 billion. During the same period in the previous year, the company posted $1.33 earnings per share. The firm’s quarterly revenue was up 15.1% on a year-over-year basis. On average, analysts forecast that Eli Lilly And Co will post 6.82 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th were paid a dividend of $0.74 per share. The ex-dividend date of this dividend was Thursday, May 14th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.84%. Eli Lilly And Co’s dividend payout ratio is presently 49.01%.

A number of analysts recently commented on LLY shares. Zacks Investment Research decreased their price objective on Eli Lilly And Co to $156.00 in a research note on Wednesday, April 29th. Cowen boosted their target price on Eli Lilly And Co from $145.00 to $160.00 and gave the stock an “outperform” rating in a report on Wednesday, April 15th. Bank of America reaffirmed a “buy” rating and set a $180.00 price target on shares of Eli Lilly And Co in a research note on Friday, June 19th. Mizuho boosted their price objective on Eli Lilly And Co from $148.00 to $155.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Finally, JPMorgan Chase & Co. raised their target price on Eli Lilly And Co from $175.00 to $190.00 and gave the company an “overweight” rating in a research note on Wednesday, June 17th. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $167.83.

In related news, major shareholder Lilly Endowment Inc sold 166,038 shares of the stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $140.78, for a total transaction of $23,374,829.64. Following the completion of the sale, the insider now owns 113,155,330 shares of the company’s stock, valued at $15,930,007,357.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Stephen F. Fry sold 14,657 shares of the firm’s stock in a transaction on Monday, March 30th. The stock was sold at an average price of $134.30, for a total value of $1,968,435.10. Following the completion of the transaction, the senior vice president now owns 110,572 shares of the company’s stock, valued at approximately $14,849,819.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,164,427 shares of company stock worth $175,530,418. Insiders own 0.09% of the company’s stock.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: Ex-Dividend

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.